Title:
USE OF IMMUNE ACTIVATOR, ANTIGEN AND ANTIBODY IN PREPARATION OF PRODUCT FOR PREVENTING AND TREATING TUMORS
Document Type and Number:
WIPO Patent Application WO/2022/110010
Kind Code:
A1
Abstract:
Provided is any of the following uses: 1) the use of an immune activator and/or an antigen in the preparation of a product for the prevention, treatment or auxiliary treatment of tumors; 2) the use of an immune activator and/or an antibody in the preparation of a product for the prevention, treatment or auxiliary treatment of tumors; 3) the use of an immune activator and/or an antigen in the preparation of a product for inhibiting the proliferation or growth of tumor cells; and 4) the use of an immune activator and/or an antibody in the preparation of a product for inhibiting the proliferation or growth of tumor cells. The immune activator is a CpG oligonucleotide; the antigen is M30 mRNA; the antibody is a monoclonal antibody, and the monoclonal antibody is PD1; the M30 mRNA is obtained by means of in vitro transcription of DNA with a sequence as shown in SEQ ID NO. 2; and the CpG oligonucleotide is as follows: 1) an oligonucleotide as shown in SEQ ID NO. 1; or 2) an oligonucleotide obtained by means of chemical modification of the oligonucleotide as shown in SEQ ID NO. 1.
More Like This:
Inventors:
HU RONGKUAN (CN)
LI QIN (CN)
ZHANG PEIZHUO (CN)
LI QIN (CN)
ZHANG PEIZHUO (CN)
Application Number:
PCT/CN2020/132222
Publication Date:
June 02, 2022
Filing Date:
November 27, 2020
Export Citation:
Assignee:
SUZHOU GENEPHARMA CO LTD (CN)
International Classes:
C12N15/11; A61K31/711; A61P35/00; A61P37/02
Domestic Patent References:
| WO2020030672A1 | 2020-02-13 |
Foreign References:
| CN109022431A | 2018-12-18 | |||
| CN107430132A | 2017-12-01 | |||
| CN108025018A | 2018-05-11 | |||
| CN107428813A | 2017-12-01 | |||
| CN111166727A | 2020-05-19 |
Other References:
SEBASTIAN KREITER; MATHIAS VORMEHR; NIELS VAN DE ROEMER; MUSTAFA DIKEN; MARTIN LÖWER; JAN DIEKMANN; SEBASTIAN BOEGEL; BARBARA SCHR: "Mutant MHC class II epitopes drive therapeutic immune responses to cancer", NATURE, vol. 520, no. 7549, 30 April 2015 (2015-04-30), London, pages 692 - 696, XP055231810, ISSN: 0028-0836, DOI: 10.1038/nature14426
ZHAO YUFEI, CHEN XIAO , LI WEI: "PD1/PD-L1 Inhibitors In the Treatment of Tumors", CHINESE JOURNAL OF CANCER BIOTHERAPY, vol. 24, no. 8, 25 August 2017 (2017-08-25), pages 904 - 911, XP055932653, ISSN: 1007-385x, DOI: 10.3872/j.issn.1007-385x.2017.08.016
RUI KUAI, XIAOQI SUN, WENMIN YUAN, YAO XU, ANNA SCHWENDEMAN, JAMES J. MOON: "Subcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy", BIOCONJUGATE CHEMISTRY, vol. 29, no. 3, 21 March 2018 (2018-03-21), US , pages 771 - 775, XP055662975, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.7b00761
GONG, N.Q. ET AL.: "Proton-driven transformable nanovaccine for cancer immunotherapy", NATURE NANOTECHNOLOGY, vol. 15, no. 12, 26 October 2020 (2020-10-26), XP037311911
ZHAO YUFEI, CHEN XIAO , LI WEI: "PD1/PD-L1 Inhibitors In the Treatment of Tumors", CHINESE JOURNAL OF CANCER BIOTHERAPY, vol. 24, no. 8, 25 August 2017 (2017-08-25), pages 904 - 911, XP055932653, ISSN: 1007-385x, DOI: 10.3872/j.issn.1007-385x.2017.08.016
RUI KUAI, XIAOQI SUN, WENMIN YUAN, YAO XU, ANNA SCHWENDEMAN, JAMES J. MOON: "Subcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy", BIOCONJUGATE CHEMISTRY, vol. 29, no. 3, 21 March 2018 (2018-03-21), US , pages 771 - 775, XP055662975, ISSN: 1043-1802, DOI: 10.1021/acs.bioconjchem.7b00761
GONG, N.Q. ET AL.: "Proton-driven transformable nanovaccine for cancer immunotherapy", NATURE NANOTECHNOLOGY, vol. 15, no. 12, 26 October 2020 (2020-10-26), XP037311911
Attorney, Agent or Firm:
SUNSHINE INTELLECTUAL PROPERTY INTERNATIONAL CO., LTD. (CN)
Download PDF: